Abstract
Although the traditional coronary risk factors have included blood pressure, cholesterol, and cigarette smoking, several other factors are now being considered. This chapter provides a sampling of some of these “newer” risk factors, particularly those that have a biologic basis. The major categories to be considered are hematologic, newer lipid particles and their metabolic considerations, vitamins and homocysteine, and aspects of glucose metabolism.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Danesh J, Collins R, Appleby P, Peto R: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998, 279: 1477–1482.
Meade TW, Brozovic M, Chakrabarti RR, et al.: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986, 2: 533–537.
Ridker PM, Vaughn DE, Stampfer MJ, et al.: Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993, 341: 1165–1168.
Thompson SG, Kienast J, Pyke SDM, et al.: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635–641.
Gebara OCE, Mittleman MA, Sutherland P, et al.: Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995, 91: 1952–1958.
Juhan-Vague I, Alessi MC: Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993, 70: 138–143.
Willich SN, Levy D, Rocco MB, et al.: Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987, 60: 801–806.
Muller JE, Tofler GH, Stone PH: Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989, 79: 733–743.
Schaefer EJ, Lamon-Fava S, Jenner JL, et al.: Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994, 271: 999–1003.
Ridker PM, Stampfer MJ, Hennekens CH: Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995, 273: 1269–1273.
Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336: 973–979.
Ridker PM, Rifai N, Pfeffer MA, et al.: Long-term effects of pravastatin on plasma concentration of C- reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100: 230–235.
Steering Committee of the Physicians’ Health Study Research Group. Final report of the aspirin component of the ongoing Physician’s’ Health Study. N Engl J Med 1989, 321: 129–135.
Peto R, Gray R, Collins R, et al.: Randomized trial of prophylactic daily aspirin in British male doctors. Br Med J 1988, 296: 313–316.
Smith SC, Jr., Blair SN, Criqui MH, et al.: Consensus Panel Statement: Preventing heart attack and death in patients with coronary disease. Circulation 1995, 92: 2–4.
Hennekens CH, Dyken ML, Fuster V: Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals • from the American Heart Association. Circulation 1997, 96: 2751–2753.
CAPRIE Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996, 348: 1329–1339.
Austin MA, Breslow JL, Hennekens CH, et al.: Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260: 1917–1921.
Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996, 276: 875–881.
Jeppesen J, Hein HO, Suadicani P, Gyntelberg F: Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998, 97: 1029–1036.
Wilson PWF, Myers RH, Larson MG, et al.: Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: The Framingham Offspring Study. JAMA 1994, 272: 1666–1671.
Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM: Apolipoprotein E alleles and risk of coronary disease: a meta-analysis. Arterioscler Thromb Vasc Biol 1996, 16: 1250–1255.
Gofman JW, Young W, Tandy R: Ischemic heart disease arthrosclerosis, and longevity. Circulation 1966, 34: 679–697.
Buring JE, O’Connor GT, Goldhaber SZ, et al.: Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 1992, 85: 22–29.
Stampfer MJ, Hennekens CH, Manson JE, et al.: Vitamin E consumption and risk of coronary heart disease in women. N Engl J Med 1993, 328: 1444 1449.
Rimm EB, Stampfer MJ, Ascherio A: Vitamin E consumption and risk of coronary heart disease in men. N Engl J Med 1993, 328: 1450–1456.
Steinberg D: A critical look at the evidence for the oxidation of LDL in atherogenesis. Atherosclerosis 1997, 131(Suppl)S5–S7.
Alpha-tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994, 330: 1029–1035.
Boushey CJ, Beresford SAS, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995, 274: 1049–1057.
Selhub J, Jacques PF, Bostom AG, et al.: Association between plasma homocysteine and extracranial carotid stenosis. N Engl J Med 1995, 332: 286–291.
Selhub J, Jacques PF, Wilson PWF, et al.: Vitamin status and intake as primary determinants of homocysteinemia in the elderly. JAMA 1993, 270: 2693–2698.
Jacques PF, Selhub J, Bostom AG et al.: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999, 340: 1449–1454.
Pyorala K: Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979, 2: 131–141.
Meigs JB, D’Agostino RB, Wilson PWF et al.: Risk variable clustering in the insulin resistance syndrome. Diabetes 1997, 46: 1594–1600.
Kuusisto J, Mykkanen L, Pyorala K, Laakso M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994, 43: 960–967.
UK Prospective Diabetes Study (UKPDS) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352: 837–853.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wilson, P.W.F. (2000). The Newer Coronary Risk Factors. In: Wilson, P.W.F. (eds) Atlas of Atherosclerosis. Current Medicine Group, London. https://doi.org/10.1007/978-1-4757-9310-9_10
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9310-9_10
Publisher Name: Current Medicine Group, London
Print ISBN: 978-1-4757-9312-3
Online ISBN: 978-1-4757-9310-9
eBook Packages: Springer Book Archive